Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03832686
Other study ID # IRB-48015
Secondary ID ENT0070NCI-2019-
Status Completed
Phase N/A
First received
Last updated
Start date April 22, 2019
Est. completion date April 6, 2023

Study information

Verified date April 2024
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vibrent Health is partnering with Stanford Cancer Center to conduct a randomized control trial (RCT) using mobile health technology to enhance adherence and improve swallowing outcomes in patients undergoing radiation therapy for head and neck cancer.


Description:

Head and neck cancer (HNC) is the 6th most common type of cancer in the world and has recently seen a dramatic rise in the United States due to a rise in the incidence of oropharyngeal cancers related to the human papillomavirus (HPV) . The majority of patients diagnosed with HNC receive radiation therapy at some point in their treatment, either in the definitive or post-operative setting. Dysphagia is a common consequence of treatment for HNC, experienced by approximately 50% of patients treated with radiation therapy. Post-treatment dysphagia has been associated with increased risk of morbidity/mortality as well as well-recognized deterioration of quality of life. Performance of swallowing exercises during radiation significantly reduces dysphagia risk; however, patient adherence to swallowing exercises during radiation treatment is limited. Thus, poor adherence stands as a major obstacle to achieving the best swallowing outcomes. In response to this, a mobile health application was developed to directly address barriers cited by patients as reasons for non-adherence. The objective is to conduct a randomized controlled trial to test the impact of the mobile application on adherence to prophylactic swallowing therapy during radiation for HNC.


Recruitment information / eligibility

Status Completed
Enrollment 98
Est. completion date April 6, 2023
Est. primary completion date March 3, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Study subjects = 18 years of age. - Fluent English speaking subjects. - Study subjects capable of providing informed consent. - Patients with newly diagnosed non-metastatic head and neck cancer of the oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx that require bilateral neck radiation. Individuals with unknown primary head and neck cancer with nodal disease necessitating bilateral radiation will also be included. - Study subjects with a previously untreated head and neck cancer diagnosis requiring a definitive course of radiotherapy requiring a prescribed dose of 60Gy or greater. - Study subjects who have either an Android or Apple iOS-based smartphone or tablet compatible with the Vibrent application. - Study subjects who have access to a sufficient monthly data plan (approximately 200 MB/month), or Internet connection. Exclusion Criteria: - Non-English speaking, or incapable of providing informed consent. - Lack of smartphone, tablet, or Internet connection. - Inability to use the Vibrent application. - Patients being treated for head and neck cancer who do not receive some form of primary, adjuvant, or neo-adjuvant radiation therapy will not be considered for the study. - Patients with recurrent disease. - Pregnant women. - Individuals under the age of 18. - Individuals with contraindications to radiation therapy.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Virtual Coach
The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.

Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Stanford Cancer Institute Palo Alto California
United States Fox Chase Cancer Center Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Stanford University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Starmer HM, Klein D, Montgomery A, Goldsmith T, McCarroll L, Richmon J, Christopher Holsinger F, Beadle B, Jain P. Head and Neck Virtual Coach: A Randomized Control Trial of Mobile Health as an Adjunct to Swallowing Therapy During Head and Neck Radiation. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Achieving at Least 50% Adherence to Swallowing Exercises Measure of overall adherence to prescribed exercise protocol, by treatment group and radiation week. 7 weeks
Secondary Patient Perceived Swallowing Impairment as Measured by the MD Anderson Dysphagia Inventory (MDADI) The MD Anderson Dysphagia Inventory (MDADI) was selected to capture and quantify the patient perception of swallowing dysfunction. It is a 20-item patient reported survey that measures the impact of dysphagia on patients with HNC. Each item is scored on a 5 point scale with 1=lower function and 5=higher function. Possible scores range from 20-100 with higher scores indicating more normal swallowing function. 19 weeks
Secondary Diet Level as Defined by the Functional Oral Intake Scale (FOIS) Functional Oral Intake Scale (measure of diet restriction). Scores range from 1-7 where lower scores reflect more limited oral intake and higher scores reflect more normal diet levels. 19 weeks
Secondary Diet Restrictions as Measured by the Performance Status Scale Head and Neck Performance Status Scale Head and Neck measures eating in public (range 0-100; higher number is indicative of better function), and normalcy of diet (range 0-100, higher number is indicative of more normal function) 7 weeks
Secondary Physiological Oropharyngeal Swallowing Impairment as Measured by the Modified Barium Swallow Impairment Profile (MBS-ImP) The Modified Barium Swallow Impairment Profile is a tool designed to quantify degree of impairment on 13 individual physiologic components visualized during a modified barium swallow where higher numbers reflect greater dysfunction. Score range: 0-4 for each physiologic component. The maximum possible Oral score is 22 and the maximum possible pharyngeal score is 29. 19 weeks
Secondary Depth of Bolus Entry Into the Laryngeal Vestibule as Measured Using the Penetration-Aspiration Scale (PAS) The Penetration Aspiration Scale measures the presence and depth of food/liquid material entering the airway and patient response to that material. This scale ranges from 1-8 with higher numbers indicating more abnormal function. 19 weeks
Secondary Severity of Impairment of Swallowing Safety and Efficiency as Measured Using the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) Scale Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) rates the safety and efficiency of the swallow. Safety and efficiency are rated on a scale of 0-4 with higher numbers indicating more abnormality. This scale also includes an overall impairment score which takes into consideration the safety and efficiency grade. 7 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Terminated NCT02521870 - A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02268344 - Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection N/A
Terminated NCT00198328 - Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma Phase 3
Recruiting NCT04858269 - First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Phase 2
Recruiting NCT05878964 - Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
Recruiting NCT03051269 - Calcium Electroporation for Head and Neck Cancer Phase 1
Completed NCT05833841 - Swallowing Function in Patients With Head and Neck Cancers N/A
Withdrawn NCT03747562 - Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients. Phase 3
Completed NCT03572829 - Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC Phase 2
Completed NCT02075385 - Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer Phase 2
Recruiting NCT02549742 - Electrochemotherapy on Head and Neck Cancer Phase 2
Completed NCT01951664 - Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors N/A
Recruiting NCT05838729 - Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer Phase 1/Phase 2
Recruiting NCT05382585 - Newer Therapeutic Targets in Head and Neck Cancers